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Objectives: to investigate whether appropriate selection in patients with infrarenal abdominal aortic aneurysms (AAA) for
transfemoral endovascular aneurysm management (TEAM) or open graft replacement (OGR) may decrease in-hospital
mortality rates (MR).
Design: analysis of a clinical series over three periods in an university vascular center. Conclusions of the second period were
drawn and prospectively applied in a third period and compared.
Methods: during the period 1989–1994 only OGR was available ðn ¼ 170Þ: In the interval 1995–2000 either OGR or
TEAM were carried out ðn ¼ 454Þ: During the period 01/2001–07/2002 the conclusions concerning selection of treatment
modality were drawn and prospectively applied in 132 consecutive patients. MR were recorded and possible significant
differences were checked.
Results: during the first period MR was 6.5%. Overall MR decreased to 3.7% in the second interval. Overall MR of the last
period was improved to 1.5% ðp , 0:05Þ: No patient died after OGR (0% vs 6.5%, p , 0:04). As all patients with
significant individual risk profiles were treated by TEAM, MR slightly increased (2.9%), but the difference remained
insignificant (2.4% in period 2).
Conclusions: risk adjusted selection of treatment modality influences the results after OGR significantly, thereby reducing
overall MR of elective AAA treatment.
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Introduction
During the last four decades open graft replacement
(OGR) has remained the standard of care in the
elective treatment of infrarenal abdominal aortic
aneurysms (AAA).1,2 Transfemoral Endovascular
Aneurysm Management (TEAM) was introduced
during the last decade and became gradually avail-
able.3,4 The endoluminal technique avoids major
procedures for surgical access, omits the need for
general anesthesia and intensive care management
therefore allowing treatment of patients considered
unfit for open surgery. The less invasiveness5 has been
shown by reduced intraoperative blood loss, shor-
tened stays in intensive care units as well as in-
hospital.6 – 8 These obvious advantages convinced
many centers to use the procedure with increasing
frequency.5 – 12 However, employing both methods of
treatment and comparing the results, expressed as
mortality as well as the probability of postoperative
midterm survival, did not show any statistically
significant differences.6 – 12 Therefore, the technology
was rejected by others. Leaving the selection of
treatment to the attending surgeon’s preference, the
decision to operate is not made at random, but is
usually based upon an evaluation of inherent risk
factors. This is obtained by employing a propensity
score adjusted analysis. Thereby we have been able to
demonstrate that TEAM offers superior in-hospital
mortality rates (MR; 4.7 vs 19.2%) and midterm
survival in patients with increased individual risk
profiles,12 and might be recommended in patients with
reduced physical status, who comprise a significant
proportion of AAA patients.13
Thus, the aim of the study was to test the strategy to
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avoid OGR and employ TEAM depending upon the
patients’ individual risk profiles in a prospectively
sampled clinical series, in an attempt to further reduce
mortality of aneurysm management.
Patients and Methods
From January 1989 to July 2002, a total of 756
consecutive patients were electively treated for infra-
renal AAA at our institution and were eligible for
analysis. Patients with thoracoabdominal or juxtarenal
aortic aneurysms, as well as those requiring cross-
clamping above the renal arteries, were excluded.
During the earliest period (1989–1994) all patients
ðn ¼ 170Þ received OGR of the dilated aortic segment.
The patient charts were reviewed, accompanying risk
factors as mentioned below were collected, the
severity of organ dysfunctions was judged according
to the American Society of Anesthesiologists (ASA)
classification (Table 1).14 The MR were calculated. Age,
sex and several markers of organ dysfunction were
recorded. Renal dysfunction was considered to be
present in patients with serum levels of creatinine
exceeding 133 mmol/l. Pulmonary dysfunction was
assumed when the results of lung function tests were
below 65% of the expected values, and/or moderate or
severe dyspnea on exertion was found. Hepatic
dysfunction was indicated by serum levels of g-
glutamyl transpeptidase (GGT) exceeding 30 IU/l.
The respective cut-off levels were chosen according
to accepted international limits15 as well as standard
thresholds of our Department of Laboratory Medicine.
Furthermore, history of heart disease, including
myocardial infarction, stable angina pectoris, balloon
dilatation of coronary arteries, bypass grafting, evi-
dence of reduced ventricular performance and pre-
sence of pulmonary hypertension was defined as a
cardiac risk factor. Additionally, diabetes, hyperten-
sion and evidence of severe cerebrovascular disease
were identified as further risk factors. In patients with
clear indications for revascularization of coronary or
carotid arteries, the respective interventional or
operative repair was done before exclusion of AAA.
Patients presenting with untreatable unstable angina
pectoris, New York Heart Association class IV func-
tion, necessity of O2-support at rest or end-stage
malignant disease were not treated for their AAA.
Likewise, patients in ASA class V were declined from
operative therapy.
During the second period (1/1995–12/2000) 454
patients received either an open surgical ðn ¼ 248Þ or a
less invasive endoluminal procedure ðn ¼ 206Þ: The
choice of treatment modality was left to the surgeon’s
preference. But it has to be assumed that the respective
decision was based upon the surgeon’s individual risk
estimation. Thus, all parameters mentioned above
were used to calculate the “propensity” for perform-
ing OGR or TEAM. Afterwards, a Cox proportional
hazard model with the “propensity score” as
additional covariate was performed to identify sig-
nificant predictors of increased 900-day mortality as
recently described.12 Patients with advanced age (i.e.
$72 years), diabetes mellitus, renal (i.e. serum
creatinine $133 mmol/l) and pulmonary dysfunction
(i.e. results of lung function tests were below 65% of
the expected values, and/or moderate or severe
dyspnea on exertion) or patients classified as ASA
class IV (see Table 1) were identified as those with an
unacceptably high risk for OGR.
In the third interval from January 2001 until July
2002, 132 patients were prospectively treated either by
OGR ðn ¼ 63Þ or TEAM ðn ¼ 69Þ according to these
criteria, i.e. patients $72 years with renal and/or
pulmonary dysfunction, patients $80 years or
patients classified ASA IV received TEAM. MR were
obtained and compared to the previous periods. In 13
patients classified as ASA IV the implantation of a
stent graft was not feasible and a conservative
approach was selected.
Surgical technique
For OGR, a transperitoneal approach via a median
laparotomy was used. Exclusion of AAA was per-
formed by implantation of commercially available
bifurcated or tubular grafts. Endoluminal stent graft-
ing was achieved by a transfemoral approach.
Table 1. ASA physical status classification system.
ASA* class Physical status
I A normal and healthy patient.
II A patient with mild systemic disease.
III A patient with severe systemic disease that is
not incapacitating.
IV A patient with incapacitating systemic disease that
is a constant threat to life.
V A moribund patient who is not expected to
survive for 24 h with or without operation.
E Emergency status: in addition to indicating
underlying ASA status (I–V), any patient
undergoing an emergency procedure is indicated
by the suffix “E”. For example, a fundamentally
healthy patient undergoing an emergency
procedure is classified as I–E. If the patient is
undergoing an elective procedure, the “E”
designation is not used.
*American Society of Anesthesiologists.
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Commercially available modular stent grafts were
implanted through an arteriotomy. In case of bifurcated
stent grafts, the extension graft for the second limb was
inserted by transcutaneous puncture or arteriotomy of
the contralateral common femoral artery.
Statistics
Age was described by medians, interquartile and 90%
ranges. Comparisons were performed by Wilcoxon
rank sum tests. All other data were processed by
bivariate transformation and described by contin-
gency table analyses, possible differences were inves-
tigated by chi-square tests. MR were described as
proportions and 90% confidence intervals were calcu-
lated. Differences in MR rates were analyzed by
Fisher’s exact tests. Risk estimation during the second
period was performed by a propensity score-adjusted
analysis as recently described.12 Concerning the
multiple comparisons problem resampling based
adjustments using a bootstrap algorithm were per-
formed whenever necessary. All statistical analyses
were carried out with the SAS program (version 6.09E)
on an IBM 4090 mainframe.
Results
Tables 2–4 summarize the physical status of the
patients, their preoperative risk profiles distributed
according to both treatment groups and compare the
three different observation periods. Tables 5 and 6
show the immediate results of treatment (in-hospital
mortality rate) in regard to the observation period and
the influence of the ASA classification.
In Table 2 it is shown that the amount of various
comorbidities has stepwise increased over time. This is
especially obvious for the risk factors pulmonary
dysfunction, cardiac disease, hypertension and dia-
betic metabolic state.
Table 3 demonstrates that the amount of patients in
reduced physical status has increased during the three
observation periods. Furthermore, it is shown that
high-risk patients were preferentially treated by
TEAM.
For the last period Table 4 shows that various
comorbidities—e.g. age, pulmonary dysfunction, car-
diac disease and hypertension—were more often
observed in a statistically significant way in the
TEAM than in the OGR group. In other words, it
was possible to transfer the considerable sicker
patients into the TEAM group for respective
treatment.
Table 5 compares the immediate results of treatment
in the three observation periods. Please note that it was
possible to improve the results of OGR, especially that
no patient died in the last interval having undergone
OGR. The price was the low increase of MR after
TEAM.
It was possible to improve the results of treatment in
ASA IV patients gradually over time, obviously due to
the proper risk adapted selection of treatment (Table 6).
Discussion
Aneurysms located in the infrarenal aortic segment are
observed most commonly.16 The prevalence is
Table 2. Demographic data, prevalence and distribution of preoperative risk factors of patients during the different treatment periods.
First period 1989–1994 ðn ¼ 170Þ Second period 1995–2000 ðn ¼ 454Þ Third period 2001–7/2002 ðn ¼ 132Þ
Age (years)
Median 70.1 71.8 72.7
Q1–Q3 65.3–75.1 66.0–75.8 64.5–78.3
90% Range 51.2–80.9 55.7–82.3 56.5–82.4
Sex
Male 159 (93.5) 412 (90.7) 114 (86.4)
Female 11 (6.5) 42 (9.3) 18 (13.6)
Pulmonary dysfunction 25 (14.7) 101 (22.2) 48 (36.4)
Renal dysfunction 27 (15.9) 61 (13.4) 19 (14.4)
Hepatic dysfunction 11 (6.5) 97 (21.4) 33 (25.0)
Cardiac disease 79 (46.5) 274 (60.4) 96 (72.7)
Cerebrovascular disease 19 (11.2) 53 (11.7) 20 (15.2)
Hypertension 91 (53.5) 303 (66.7) 105 (79.5)
Diabetes 12 (7.1) 62 (13.7) 21 (15.9)
Malignancy 6 (3.5) 61 (13.4) 19 (14.4)
Values are expressed as n (%) unless otherwise indicated. Q1–Q3 indicates interquartile range.
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significantly correlated with age, reaching up to 10% in
men older than 80 years.13 As life expectancy in the
western industrialized countries increases, an optimal
management of AAA might become an inevitable
concern.
General considerations
Prophylaxis of rupture seems to be the only reasonable
treatment since MR after emergency surgery reaches
50%17 and overall mortality rate of aneurysm rupture
approaches 80%.18 The aim of any elective interven-
tion in patients with AAA is the prevention of rupture
by avoiding exsanguinating hemorrhage and death.
Any therapeutic decision-making has to balance MR
against the risk of rupture. In the early years of elective
AAA surgery MR were reported as high as 20%.19
Improvements in surgical techniques, perioperative
anesthesiologic and intensive care management have
stepwise decreased this figure. Currently, MR between
5 and 10% are published in national and regional
series,17,20 3–5% in institutional ones1,21 and even
lower percentages emerged from specialized centers.22
A similar development is obvious in the own clinical
series by investigating the different observation
periods.
Need for alternative treatment options
Several risk factors are known to influence the post-
operative results. Age, chronic obstructive pulmonary
disease, kidney dysfunction, diabetes and significant
cardiac disease are associated with unfavorable out-
comes.1,12,23 – 25 The uneven distribution of these
factors in favor of the OGR group is clearly demon-
strated in Table 4. It is reasonable to summarize several
risk factors under the term “reduced physical status”
as expressed by the ASA classification system14 given
in Table 1. As already shown, MR increases in parallel
to higher ASA status12 irrespective, which method of
treatment is selected. Since the population is aging the
prevalence of comorbidities increases. Physicians
caring for vascular patients are more and more
confronted with patients in reduced physical status,
who are unfit for OGR and/or general anesthesia. In
such patients the risk of OGR outweighs the benefits of
rupture prophylaxis. Thus, there was a demand for
alternative concepts using minimal invasive tech-
niques. Artificial thrombosis of the aneurysm sac, in
order to prevent rupture and extra-anatomic bypass
grafting to preserve blood supply to the lower body
half, was advocated in anecdotal reports.26,27 Because
thrombosis of the sac alone did not protect fromTa
b
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rupture reliably the method was abandoned soon. But
the principal idea was seized and later on the TEAM
approach for AAA exclusion evolved.3,4
By using the transfemoral endoluminal route the
surgical burden is reduced compared to OGR. Until
recently, this assumption was only supported by
reduction of blood loss during the intervention,
followed by decreased length of stay at ICU and in-
hospital.6 – 8 Without risk adjustments no significant
improvements in MR, as well as mid-term survival
rates of up to 5 years could be found.6 – 12 Additionally,
different types of endoleaks leading to possible
secondary rupture with the need of reinterventions
or conversions to OGR were observed.28 The precon-
dition of certain aneurysm anatomy for the implan-
tation of endovascular grafts further limited its use5
and the necessity of life long graft surveillance
prompted some investigators to question the value of
the method for routine use, and even called it “a failed
experiment”.29
Statistical considerations
To obtain evidence-based reliable treatment compari-
sons leading to valid recommendations (so called
grade A recommendations according to Sackett),30
people prefer to see properly designed, ethically
feasible and well-controlled randomized trials, having
enrolled a sufficient number of patients prospectively
and using appropriate statistical tools. Allocating
patients randomly into alternative treatment groups
produces an optimal balance of both the patients’
number and characteristics. This sampling process
needs to follow very strict regulations, forcing ASA
class IV patients to face a major surgical procedure like
OGR, a measure which might be questioned. There-
fore, the interest in methods allowing valid but not
prospectively randomized comparisons increased.
New methods for dealing with observationally
sampled data based on so called “propensity scores”
have attracted attention recently.31 Especially, investi-
gations of major surgical vs minimal invasive
Table 4. Demographic data, prevalence and distribution of preoperative risk factors of patients prospectively assigned to respective
treatment modality in the third period 2001–7/2002.
TEAM* ðn ¼ 69Þ OGR† ðn ¼ 63Þ Statistical significance P ,
Age (years)
Median 77.9 65.8 0.001
Q1–Q3 72.1–80.4 60.3–73.7
90% Range 64.8–85.4 53.3–77.3
Sex
Male 58 (84.1) 56 (88.9) 0.419
Female 11 (15.9) 7 (11.1)
Pulmonary dysfunction 38 (55.1) 10 (15.9) 0.001
Renal dysfunction 13 (18.8) 6 (9.5) 0.128
Hepatic dysfunction 20 (29.0) 13 (20.6) 0.268
Cardiac disease 62 (89.9) 34 (54.0) 0.001
Cerebrovascular disease 14 (20.3) 6 (9.5) 0.085
Hypertension 62 (89.9) 43 (68.3) 0.002
Diabetes 15 (21.7) 6 (9.5) 0.055
Malignancy 11 (15.9) 8 (12.7) 0.596
Values are expressed as n (%) unless otherwise indicated. Q1–Q3 indicates interquartile range.
*Transfemoral Endoluminal Aneurysm Management.
†Open Graft Replacement.
Table 5. Changes of in-hospital mortality during the different treatment periods.
In-hospital mortality First period 1989–1994 ðn ¼
170Þ
Second period 1995–2000 ðn ¼
454Þ
Third period 2001–7/2002
ðn ¼ 132Þ
% (CI‡) n % (CI‡) n % (CI‡) n
Overall 6.5 (4.1–10.4) 11 of 170 3.7 (2.6–5.6) 17 of 454 1.5 (0.6–4.7) 2 of 132
OGR* 6.5 (4.1–10.4) 11 of 170 4.8 (3.1–7.7) 12 of 248 0.0 (0.0–4.6) 0 of 63
TEAM† – – 2.4 (1.3–5.0) 5 of 206 2.9 (1.2–8.7) 2 of 69
*Open Graft Replacement.
†Transfemoral Endoluminal Aneurysm Management.
‡90% Confidence interval.
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procedures in high- and low-risk patients become
ethically feasible. In general, two completely different
groups of patients in respect of individual risk factors
are compared. For reducing bias from these differences
in distributions of risk factors in the respective
treatment group and from intentional selection of the
different treatment modalities propensity score adjust-
ments32 and respective subgroup analysis are per-
formed. In the meantime, this scientific approach has
been honored by the reviewers of highly ranked
journals.
By employing such a propensity score adjusted
analysis, we have been able to demonstrate, that the
choice of intervention influences the result signifi-
cantly, and the less invasive TEAM is capable to
reduce mortality in selected patients. In patients with
advanced age, with pulmonary or renal dysfunctions,
classified as ASA class IV, MR was reduced from 19.2%
(OGR) to 4.7% (TEAM). So it seemed justified to select
the treatment depending upon the individual risk
profile.12
To strengthen the level of evidence, we decided to
validate the results of the second interval in a clinical
study, comparing MR after prospectively risk adjusted
treatment during the most recent period with MR in
the first period (1989–1994) when TEAM was not yet
available. By avoiding OGR and shifting high-risk
patients into the TEAM group intentionally, it was
possible to avoid death from any cause in the open
surgery group. Although mortality following TEAM
increased slightly, the difference remained clinically
and statistically insignificant (i.e. 2.4 vs 2.9%). The
overall MR following AAA exclusion after both
treatment modalities was reduced to 1.5%. When
compared to a control group sampled before the
availability of TEAM, a significant difference was
found (1.5 vs 6.5%, p , 0:05). In parallel, the overall
number of therapeutic interventions increased. As
morphological criteria for surgical repair (diameter of
AAA .5 cm or significant progression) remained
unchanged over the observation period, the growing
number of interventions is primarily due to offering
treatment also to high-risk patients. During the last
period ASA class IV patients were intentionally
treated by TEAM. Only in three high-risk patients in
whom TEAM was not applicable OGR was performed
because of a large aneurysm (diameter .8 cm) or
extensive progression of AAA diameter (.1 cm
within 6 months). In case of smaller aneurysms and
impossibility of implantation of stent grafts a con-
servative strategy was selected in 13 patients during
2001–7/2002.
Considering that since introduction of the above
described concept no patient died after OGR, the level
of evidence achieved by the already published
propensity score analysis12 is still improving.
Concluding Remarks
The TEAM approach is a valuable tool in the active
AAA treatment of selected patients. It is responsible
for the reduction of overall MR as well as MR after
elective open AAA exclusion by avoiding the employ-
ment of OGR in high-risk patients. Thus TEAM is an
important element of a successful concept for AAA
management.
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